ZADITOR Drug Patent Profile

When do Zaditor patents expire, and what generic alternatives are available?

Zaditor is a drug marketed by Alcon Pharma and Alcon Pharms Ltd and is included in two NDAs.

The generic ingredient in ZADITOR is ketotifen fumarate. There are five drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ketotifen fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zaditor

A generic version of ZADITOR was approved as ketotifen fumarate by APOTEX INC on May 9^th, 2006.

Summary for ZADITOR

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	4
Patent Applications:	1,861
Drug Prices:	Drug price information for ZADITOR
DailyMed Link:	ZADITOR at DailyMed

See drug prices for ZADITOR

Recent Clinical Trials for ZADITOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sen-Jam Pharmaceutical	Phase 2
National University, Singapore	Phase 2
Bausch & Lomb Incorporated	Phase 3

See all ZADITOR clinical trials

Pharmacology for ZADITOR

Drug Class	Histamine-1 Receptor Inhibitor
Mechanism of Action	Histamine H1 Receptor Antagonists

Paragraph IV (Patent) Challenges for ZADITOR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZADITOR	Ophthalmic Solution	ketotifen fumarate	0.025%	021066	1	2004-12-23

US Patents and Regulatory Information for ZADITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Pharma	ZADITOR	ketotifen fumarate	SOLUTION/DROPS;OPHTHALMIC	021066-002	Oct 19, 2006		DISCN	Yes	No
Alcon Pharms Ltd	ZADITOR	ketotifen fumarate	SOLUTION/DROPS;OPHTHALMIC	077200-001	Sep 2, 2008		OTC	No	Yes

International Patents for ZADITOR

See the table below for patents covering ZADITOR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1172098	Composition ophthalmologique à base de ketotifène (Eye drop composition comprising ketotifen)
Hungary	0202243
Poland	202496
Poland	352382
European Patent Office	0938896
Japan	2011168601	AUTOCLAVABLE PHARMACEUTICAL COMPOSITION CONTAINING CHELATING AGENT
World Intellectual Property Organization (WIPO)	0107049

ZADITOR (ketotifen fumarate) — Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

ZADITOR (ketotifen fumarate) is an over-the-counter (OTC) antihistamine eye drop used for allergic conjunctivitis. Its market dynamics are shaped by (1) OTC conversion and substitution in seasonal allergy periods, (2) competitive intensity from other OTC ocular antihistamines and mast-cell stabilizers, (3) store-brand and private-label pressure, and (4) the ability to maintain share through regulatory continuity and continuous availability. Financial trajectory is driven less by patent-driven pricing power and more by volume durability, seasonal peaks, and channel penetration.

What market is ZADITOR in, and what drives demand?

ZADITOR competes in the U.S. (and other markets where marketed) topical ophthalmic OTC allergy segment. The demand cycle is strongly seasonal, with peaks during spring and early summer. Key demand drivers include:

• Seasonality: consumer purchasing concentrates in allergy months, creating revenue volatility by quarter rather than sustained growth.
• Switching friction: consumers often trial new products when formulations are similar in effect or price, increasing substitution.
• Symptom-led repeat buying: once a consumer uses a product during a season, they re-buy during the next season if satisfaction is high.

The product’s active ingredient, ketotifen fumarate, is used to treat itching associated with allergic conjunctivitis. The commercial value is tied to sustained OTC recognition and shelf space rather than exclusivity.

How does competitive intensity shape ZADITOR’s pricing and share?

The competitive set for OTC allergic conjunctivitis eye drops typically includes:

• other OTC ophthalmic antihistamines
• mast-cell stabilizers
• combination products where available OTC
• store-brand options in similar therapeutic categories

In practice, OTC ocular allergy is a substitution market. If efficacy expectations are met, consumers choose primarily by:

• Price-per-bottle
• Shelf availability
• Promotional runs (end caps, seasonal displays)
• Copay dynamics are irrelevant OTC but value perceptions are not

That structure pressures list price and supports promo discounting. For established brands like ZADITOR, maintaining share usually means defending channel placement and sustaining promotional intensity during seasonal windows.

What are ZADITOR’s distribution and channel dynamics?

ZADITOR is sold through standard OTC pharmaceutical channels, including:

• mass retail pharmacies and big-box chains
• grocery and club retail
• e-commerce marketplaces

Channel dynamics influence financial trajectory because:

• Seasonal inventory planning matters: retailers order ahead of allergy peaks.
• Online price competition can compress net revenue through discounting.
• Promotions in mass retail can raise unit volume but dilute net price if margin management is not tight.

For consumer-facing OTC products, revenue growth is often a function of unit volume plus net price discipline. ZADITOR’s trajectory therefore depends on the balance of promotional spending versus price retention in seasonal months.

How does regulation affect the longevity and commercial durability of ZADITOR?

ZADITOR’s durability is supported by the fact that ketotifen formulations can remain on the market without patent-driven interruptions, as long as regulatory and manufacturing requirements are maintained. For OTC ophthalmic drugs:

• Formulation continuity helps preserve consumer familiarity and channel routines.
• Label claims and indication wording influence switching; conservative label positioning supports sustained use.

Because the product is OTC, commercial risk is less about exclusivity cliffs and more about:

• manufacturing continuity
• supply reliability
• labeling consistency
• competitive entries

What is the financial trajectory pattern you should expect for ZADITOR?

Expected revenue shape in an OTC allergy category

ZADITOR’s financial trajectory typically tracks:

• Annual seasonality pattern: higher sales in allergy months, lower in off-season.
• Year-over-year unit movement: driven by retailer buying cycles, promotional activity, and competitive entry.
• Net price pressure: recurring promo intensity and private-label substitution constrain margin expansion.

In an OTC segment without meaningful patent protection at the consumer level, the typical path is:

• stable brand volume
• gradual mix shift if private label expands
• earnings volatility around promo intensity and retailer replenishment timing

What to monitor for trend confirmation

For an installed OTC brand like ZADITOR, business-critical indicators are:

• Units per season (not just total annual revenue)
• Net revenue per bottle (discounting and promo mix)
• Channel mix changes (mass retail versus online)
• Promotional cadence (frequency and depth of discounting)
• Listing wins or losses in key accounts

Does patent status drive ZADITOR’s economics, or is it mainly volume-led?

ZADITOR’s economics are primarily volume-led and channel-led, not patent-exclusivity-led.

Unlike prescription branded products where patent walls can sustain high price and protect margin, an OTC ophthalmic allergy product’s competitiveness is dominated by:

• functional substitutability (similar therapeutic class expectations)
• retailer and consumer price sensitivity
• private label and generics availability (where category competitors exist)
• seasonal replenishment behavior

The practical implication is that ZADITOR’s financial trajectory is more correlated with category health and distribution execution than with litigation or exclusivity events.

What are likely upside and downside forces on ZADITOR’s near-to-mid-term trajectory?

Upside forces

• Sustained brand trust and repeat-season buying
• Stronger seasonal retail execution (better end-cap visibility, better availability)
• E-commerce share capture if pricing is competitive and supply is reliable
• Regulatory continuity that supports consistent shelf identity

Downside forces

• Competitive discounting by large OTC players during peak season
• Private-label expansion in mass retail channels
• Online price compression from marketplace sellers
• Supply disruptions that cause missed peak demand and reduce repeat buying habits

How should investors and operators interpret ZADITOR’s market dynamics?

For operators:

• treat ZADITOR as a seasonal, promo-managed SKU and manage margin through net pricing and mix, not list price.
• protect retailer relationships ahead of allergy months; channel confidence affects in-season replenishment.

For investors:

• view ZADITOR as a category share and execution story rather than an exclusivity story.
• expect revenue growth to come from unit share gains, not from pricing power.

Key Takeaways

• ZADITOR is an OTC allergic conjunctivitis eye drop where demand is season-led and substitution risk is high.
• Competitive intensity and private-label presence constrain pricing, making net revenue and promo discipline central to margin performance.
• The financial trajectory is expected to show seasonal peaks, with off-season softness and year-to-year volatility tied to promotional cadence and retailer replenishment.
• Patent exclusivity is not the dominant driver; durability depends on distribution execution, manufacturing continuity, and brand repeat-season buying.

FAQs

1) What market segment does ZADITOR belong to?

ZADITOR belongs to the OTC ophthalmic allergy (allergic conjunctivitis) segment, where consumers buy based on symptom relief during seasonal peaks.

2) What primarily drives ZADITOR’s sales?

Seasonality and retailer channel execution drive unit volume, while competitive promo activity drives net price and margin outcomes.

3) Does ZADITOR benefit from patent exclusivity?

Its commercial position functions primarily as an established OTC brand rather than as a patent-protected prescription asset, so economics are more volume- and channel-led than exclusivity-led.

4) What risks can reduce ZADITOR’s financial performance?

Private-label and competitor discounting, online price compression, and supply or listing disruptions during the peak allergy window.

5) What operational metrics best predict ZADITOR’s financial trajectory?

Units per season, net revenue per bottle (promo and mix effects), channel mix (mass retail vs e-commerce), and promotional cadence.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Labeling for ZADITOR (ketotifen fumarate) ophthalmic solution. FDA Drug Labels. https://www.accessdata.fda.gov/